We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Lipid Profiles Investigated for Coronary Heart Disease Patients

By LabMedica International staff writers
Posted on 23 Nov 2016
Lipoprotein (a) (Lp (a)) excess is an independent risk factor of coronary artery disease (CAD) and has shown wide ethnic variations and lipid parameters used in the assessment and management of risk factors for CAD may not reflect accurately the disease or its severity.

Risk factors for Cardio Vascular Disease (CVD) comprise dyslipidemia, diabetes, hypertension, obesity, sedentary lifestyle, smoking, alcohol, family history, menopause and advancing age. More...
Furthermore, homocysteine, fibrinogen, lipoprotein(a), low density lipoprotein particle size and C-reactive protein are the conditional risk factors that contribute to CVD.

Medical scientists at the University of Sri Jayewardenepura (Nugegoda, Sri Lanka) conducted a prospective cross sectional study during the years 2013 and 2014. The study sample consisted of 102 consenting patients awaiting Coronary Artery Bypass Graft (CABG) at the Cardiothoracic Unit of the local hospital. The majority of the patients (43.1 %) were between 51 and 60 years with 4.9 % less than 40 years. The mean age of male and female patients was 56.9 ± 10 and 57.8 ± 7.

Pre-operative blood samples were collected into plain tubes and the serum separated. Lp(a) content was measured by immunoturbidimetric method (Thermo Fisher Scientific, Helsinki, Finland) . The absorbance of the immune-complex, produced from Lp(a) and anti-serum was measured at 340 nm on a Thermo Scientific Konelab 20XT clinical chemistry automated analyzer. Data on total cholesterol, low density lipoprotein cholesterol (LDLc), high density lipoprotein cholesterol (HDLc), and triglyceride were collected from each patient’s data records and TC:HDLc ratio calculated.

The scientists reported that total cholesterol (TC), LDL cholesterol and HDL cholesterol of the total study sample (average ± SD) were, 150 ± 36 mg/dL, 92 ± 36 mg/dL and 34 ± 9 mg/dL respectively with no significant difference irrespective of being on pharmacological treatment or not. All lipid parameters were significantly high in females. The average Lp(a) was 50 ± 38 mg/dL with no significant difference in males or females independent of being on treatment (50 ± 39 mg/dL) or not (49 ± 39 mg/dL) and above the cut off value (30 mg/dL).

The authors concluded that despite pharmacological interventions 27 % of the study population had high LDLc and majority low HDLc. Mean Lp(a) was in excess irrespective of risk factors or being on treatment or not and is confirmed as an independent, potential marker for assessing the susceptibility for CAD especially in those with other intermediate risk factors but considered non-hyperlipidemic by conventional methods. The study was published on November 8, 2016, in the journal BMC Cardiovascular Disorders.

Related Links:
University of Sri Jayewardenepura
Thermo Fisher Scientific

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.